Newland Pharmaceutical Co., Ltd. (SHE:301277)

Market Cap	5.00B +28.5%
Revenue (ttm)	670.43M -4.0%
Net Income	123.72M -24.6%
EPS	0.32 -24.9%
Shares Out	392.08M
PE Ratio	40.40
Forward PE	n/a
Dividend	0.29 (2.24%)
Ex-Dividend Date	Apr 16, 2025

Volume	3,071,374
Average Volume	3,704,478
Open	12.53
Previous Close	12.52
Day's Range	12.47 - 12.77
52-Week Range	9.94 - 18.38
Beta	0.35
RSI	55.56
Earnings Date	Mar 20, 2026

About Newland Pharmaceutical

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. It provides pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. The company also offers APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, l...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,042
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301277

Financial Performance

In 2024, Newland Pharmaceutical's revenue was 726.44 million, an increase of 11.51% compared to the previous year's 651.44 million. Earnings were 173.63 million, an increase of 9.22%.